Despite representing only 12% of total Asian out-licensing deals, Korean biotechs account for a disproportionately high 20% of "first-in-class" partnerships. This indicates a strong appetite for novel science and high-risk, high-reward innovation, challenging the stereotype of Asian biotech as purely "fast followers."

A VC advises Korean entrepreneurs to abandon gradual US entry strategies. The effective model is to "parachute" in—relocating solo to a hub like Boston and immersing oneself in the network. This radical, face-time-centric approach is deemed essential for building the momentum needed for US investment and partnerships.

A key debate surrounds the Korean biotech ecosystem: are companies building with a global mindset from day one? Some US investors argue that Korean firms focus too much on their domestic market initially, requiring significant "handholding" to succeed globally, a view contested by local leaders.

South Korea's biotech sector is poised for a 'J-curve' of rapid growth. However, realizing this potential depends on overcoming two critical hurdles: accessing sufficient capital to fund development through key value inflection points and building local expertise in global clinical strategy.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

Japan's biotech ecosystem is evolving with a new, successful model for creating cross-border companies. US venture firms are partnering with Japanese academia, combining American management expertise and capital with Japan's strong science and cost-effective R&D to build globally competitive biotechs from their inception.

A Boehringer Ingelheim executive noted a key differentiator of Korean biotechs: they enter initial partnership discussions with a well-defined strategy and understanding of their needs. This "readiness to partner" accelerates deal-making and demonstrates a higher level of business sophistication compared to many global counterparts.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

Unlike markets that can sustain 'me-too' drugs, South Korean biotechs strategically focus on high-risk areas like novel biology and diverse modalities. This high 'innovation quotient' is their necessary and deliberate path to global competitiveness, embracing target and modality risk as a core strategy.